You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-NFkB p105 / p50 antibody (ab31412)

CodeSizePriceAbpointsAvailability
    
 
  • -

  •   
  •   
  •   
  •  

  •  
  •  
  •  

  •  
Updating...

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »

Overview

Product name

Anti-NFkB p105 / p50 antibody
See all NFkB p105 / p50 products (26) ...

Description

Rabbit polyclonal to NFkB p105 / p50

Specificity

Antibody detects endogenous levels of NFkB p105/p50 protein around Serine 907.

Tested applications

IHC-P, ICC/IF, WB, IP, ELISAmore details

Cross reactivity

Reacts with

Human

Immunogen

Synthetic non-phosphopeptide derived from Human NFkB p105/p50 around the phosphorylation site of Serine 907.

Positive control

Extracts fo Hela cells, breast carcinoma tissue.

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Storage buffer

Preservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, PBS (without Mg2+ and Ca2+), 150mM Sodium chloride, pH 7.4

Concentration

Concentration information loading...

Purity

Immunogen affinity purified

Clonality

Polyclonal

Isotype

IgG

  • Immunohistochemistry (Paraffin-embedded sections) - NFkB p105/p50 antibody (ab31412)Immunohistochemistry (Paraffin-embedded sections) - NFkB p105/p50 antibody (ab31412) image (enlarge)

  • Western blot - NFkB p105/p50 antibody (ab31412)Western blot - NFkB p105/p50 antibody (ab31412) image (enlarge)

  • Immunocytochemistry/ Immunofluorescence-NFkB p105 / p50 antibody(ab31412)Immunocytochemistry/ Immunofluorescence-NFkB p105 / p50 antibody(ab31412) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab31412 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Target

Function

NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.

Sequence similarities

Contains 7 ANK repeats.
Contains 1 death domain.
Contains 1 RHD (Rel-like) domain.

Domain

The C-terminus of p105 might be involved in cytoplasmic retention, inhibition of DNA-binding, and transcription activation.
Glycine-rich region (GRR) appears to be a critical element in the generation of p50.

Post-translational
modifications

While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.
Polyubiquitination seems to allow p105 processing.
S-nitrosylation of Cys-61 affects DNA binding.

Cellular localization

Nucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor.

Target information above from: UniProt accessionP19838 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • DNA binding factor KBF1 EBP1 antibody
  • DKFZp686C01211 antibody
  • DNA binding factor KBF1 antibody
  • DNA binding factor KBF1 EBP1 antibody
  • DNA-binding factor KBF1 antibody
  • EBP 1 antibody
  • EBP-1 antibody
  • EBP1 antibody
  • KBF1 antibody
  • MGC54151 antibody
  • NF kappa B antibody
  • NF kappabeta antibody
  • NF kB1 antibody
  • NFKB 1 antibody
  • NFKB p105 antibody
  • NFKB p50 antibody
  • NFKB1 antibody
  • NFKB1_HUMAN antibody
  • Nuclear factor kappa B DNA binding subunit antibody
  • Nuclear factor NF kappa B p105 subunit antibody
  • Nuclear factor NF kappa B p50 subunit antibody
  • Nuclear factor NF-kappa-B p50 subunit antibody
  • Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibody
  • Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibody
  • p84/NF-kappa-B1 p98 antibody
see all

Anti-NFkB p105 / p50 antibody images:

  Immunohistochemistry (Paraffin-embedded sections) - NFkB p105/p50 antibody (ab31412)

Immunohistochemistry (Paraffin-embedded sections) - NFkB p105/p50 antibody (ab31412)

ab31412 at 1/50, staining NFkB p105/50 in paraffin embedded human breast carcinoma using immunohistochemistry.

  Western blot - NFkB p105/p50 antibody (ab31412)

Western blot - NFkB p105/p50 antibody (ab31412)

All lanes : Anti-NFkB p105 / p50 antibody (ab31412) at 1/500 dilution

Lane 1 : Extracts of Hela cells.
Lane 2 : Extracts of Hela cells. Antibody pre-incubated with synthesized peptide.


Predicted band size : 105 kDa

  Immunocytochemistry/ Immunofluorescence-NFkB p105 / p50 antibody(ab31412)

Immunocytochemistry/ Immunofluorescence-NFkB p105 / p50 antibody(ab31412)

ICC/IF image of ab31412 stained MCF7 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab31412, 1æg/ml) overnight at +4øC. The secondary antibody (green)ÿwas Alexa Fluor© 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor© 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43æM.

References for Anti-NFkB p105 / p50 antibody (ab31412)

ab31412 has not yet been referenced specifically in any publications.

Publishing research using ab31412? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"